10

Loading video...

Melissa Fleur Afshar

By Melissa Fleur Afshar

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


There may be one constant in Alzheimer’s disease, despite the different biological profiles seen among patients, with that being similar patterns of reduced activity in key areas of the brain.

That is one of the findings from a new study which examined how blood-brain barrier dysfunction may be linked to changes in brain metabolism, and what harm reduced brain metabolism could do. While two groups of assessed Alzheimer’s patients showed similar reductions in glucose metabolism, researchers found that the biological factors associated with those changes differed, pointing to potentially distinct pathways of brain dysfunction.

“Alzheimer's disease is often associated with the pathological accumulation of amyloid plaques and tau tangles, but this study highlights the potential importance of blood-brain barrier dysfunction in a certain subset of patients,” Dr. Amy Reichelt, a behavioral neuroscientist and Amble Health advisor, told Newsweek.

Read More on Science

Newsweek reached out via email to the study’s authors, Professor Alessandro Martorana and Dr. Chiara Bonomi, for more information.

Different Biology, Similar Changes in the Brain

Alzheimer’s is characterized by accumulations of amyloid-beta and tau proteins that contribute to neuronal dysfunction and cognitive decline. However, patients do not always have the same biological profile.

The findings, published in Aging, examined 66 patients along the Alzheimer’s disease continuum while 41 cognitively healthy participants made up a control group.

Researchers then separated the patients into two groups using biomarkers for amyloid accumulation, tau pathology and neurodegeneration. One group showed evidence of all three abnormalities. The other showed only amyloid pathology and neurodegeneration without elevated phosphorylated tau.

A neurologist observes brain scans at a medical facility.

...

Using advanced imaging, researchers were able to measure levels of glucose metabolism, an indicator of brain activity. Cerebrospinal fluid biomarkers were also used to assess Alzheimer’s-related changes, while the ratio of albumin in cerebrospinal fluid to serum served as an indicator of blood-brain barrier integrity.

The blood-brain barrier regulates which substances can pass from the bloodstream into brain tissue. Disruption of that system can alter the brain’s environment and potentially affect neuronal health.

Both Alzheimer’s groups showed reduced glucose metabolism in temporoparietal areas involved in memory and cognitive processing, including regions connected within the default mode network. What was associated with that decline, however, differed.

In patients with elevated tau biomarkers, metabolism was associated with tau-related measures. Among those without elevated phosphorylated tau, poorer metabolism in posterior brain regions was instead associated with greater blood-brain barrier dysfunction and amyloid-related changes. That group also had higher average albumin ratios, suggesting greater barrier impairment.

“The researchers found that two groups of patients with Alzheimer's-related biomarkers showed similar reductions in brain glucose metabolism as a proxy for brain activity,” Reichelt said. “However, the biological markers of tau and amyloid plaques associated with these changes differed.

“This suggests that similar patterns of brain dysfunction may involve different biological processes,” she added.

Why the Blood-Brain Barrier Matters

Reichelt said chronic systemic inflammation, metabolic dysfunction and cardiovascular disease can damage vascular health and potentially affect blood-brain barrier integrity. Increased permeability may contribute to neuroinflammation and the activation of microglia—innate immune cells tasked with clearing out toxic waste—potentially disrupting neuronal communication.

Diet, physical activity, sleep and stress can influence wider inflammatory and metabolic processes, the behavioral neuroscientist said. The study also found an association between hypertension and metabolic changes in some frontal brain regions, although the relationship differed between the two Alzheimer’s groups.

However, Reichelt cautioned that the study did not measure neuroinflammation or microglial activation, investigate lifestyle factors or establish that blood-brain barrier dysfunction causes Alzheimer’s.

The research was retrospective and observational and involved a relatively small group, meaning it identifies associations rather than cause and effect. Further research will be needed to establish how blood-brain barrier dysfunction relates to disease progression.

“The findings, importantly, highlight the complexity of Alzheimer's involving interactions between amyloid, tau, vascular integrity, and brain metabolism,” Reichelt said.

Reference

Ricci, F., Bonomi, C. G., Martorana, A. et al. (2026). Brain glucose metabolism and blood-brain barrier permeability in Alzheimer’s disease continuum. Aging. https://doi.org/10.18632/aging.206393.

Contact Newsweek editors on this story: Kara Dolman and Paul Donnelley.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines